Objective: To investigate the diagnostic value of serum and urinary Hugl-2 gene methylation in renal cell carcinoma(RCC). Methods: Hugl-2 mRNA and protein expression and gene methylation were analyzed using bioinformatics analysis tool, and its correlation with the prognosis was also evaluated. The tumor tissue, matched non-cancerous renal parenchyma, serum and urine samples from 148 patients with RCC who underwent radical nephrectomy from May 2018 to March 2021 in our urological department were collected, while age and sex matched 150 non-cancer patients matched by age and sex ere also enrolled. The methylation of Hugl-2 gene in tissues, serum and urine was detected by methylation-specific PCR. Results: Based on bioinformatics analysis, data from the TCGA database showed that the expression of Hugl-2 mRNA and protein in RCC tissues was lower than that in normal tissues(P<0.05), while the methylation level of Hugl-2 gene was higher than that of normal tissue(P<0.05). High methylation levels of Hugl-2 were associated with poor overall survival in RCC patients, based on a network of tools known as LinkedOmics(Log-rank P<0.001). In the analysis of clinical samples, the methylation level of Hugl-2 gene in RCC tissue samples was higher than that in matched adjacent non-cancerous renal parenchyma tissue samples(P<0.05). In addition, the level of Hugl-2 gene methylation in serum and urine of patients with RCC was higher than that of non-cancer control group(P<0.05). The methylation level of Hugl-2 gene was positively correlated with the methylation level of Hugl-2 gene in serum and urine of patients with RCC by Spearman correlation coefficient analysis(rs=0.352, 0.486, P<0.001). Hypermethylation of Hugl-2 gene was associated with TNM Ⅲ-Ⅳ stage(P<0.05). The area under ROC curve(AUC) of detecting Hugl-2 gene methylation in serum and urine was 0.818(95%CI:0.770-0.867) and 0.958(95%CI:0.935-0.980), respectively, and the AUC of urine was higher than that of serum(P<0.001). Conclusion: The methylation level of Hugl-2 gene in serum or urine samples is expected to be an diagnostic method for RCC, especially the methylation level of Hugl-2 gene in urine is more effective. |
[1] ESCUDIER B,PORTA C,SCHMIDINGER M,et al.ESMO Guidelines Committee.Electronic address:clinicalguidelines@esmo.org.Renal cell carcinoma:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2019,30(5):706-720.
[2] GRAY R E,HARRIS G T.Renal cell carcinoma:diagnosis and management[J].Am Fam Physician,2019,99(3):179-184.
[3] 李显,丁杰,岑祥莹,等.组蛋白赖氨酸特异性去甲基化酶1相互作用蛋白的研究进展[J].现代医学,2020,48(9):1224-1229.
[4] EVELONN E A,DEGERMAN S,KOHN L,et al.DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma(ccRCC)[J].Tumour Biol,2016,37(8):10219-10228.
[5] 李川川.肝癌组织hugl-1异常剪接体的功能的研究[D].济南:山东大学,2012.
[6] NAM K H,KIM M A,CHOE G,et al.Deregulation of the cell polarity protein lethal giant larvae 2(Lgl2) correlates with gastric cancer progression[J].Gastric Cancer,2014,17(4):610-620.
[7] MIAO Y,CAO F,LI P,et al.DNA methylation of Hugl-2 is a prognostic biomarker in kidney renal clear cell carcinoma[J].Clin Exp Pharmacol Physiol,2020,48(1):44-53.
[8] YANG K,WANG L,LE J,et al.Cell polarity:regulators and mechanisms in plants[J].J Integr Plant Biol,2020,62(1):132-147.
[9] CALLEJA M,MORATA G,CASANOVA J.Tumorigenic properties of drosophila epithelial cells mutant for lethal giant larvae[J].Dev Dyn,2016,245(8):834-843.
[10] DANIEL S G,RUSS A D,GUTHRIDGE K M,et al.miR-9a mediates the role of Lethal giant larvae as an epithelial growth inhibitor in Drosophila[J].Biol Open,2018,7(1):bio027391.
[11] 尚维伟,王亮,陈信浩.结直肠癌组织TRIM58表达、基因甲基化状态及临床意义[J].现代医学,2020,48(8):948-954.
[12] SKVORTSOVA K,STIRZAKER C,TABERLAY P.The DNA methylation landscape in cancer[J].Essays Biochem,2019,63(6):797-811.
[13] NUZZO P V,BERCHUCK J E,KORTHAUER K,et al.Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes[J].Nat Med,2020,26(7):1041-1043.
[14] 张慧娟,郑闪,冯晓莉.成人乳头状结构的肾细胞癌的诊断及鉴别诊断[J].诊断病理学杂志,2020,27(12):904-908,912. |